Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline

J. Antonelle deMarcaida, Steven R. Schwid, William B. White, Karen Blindauer, Stanley Fahn, Karl Kieburtz, Matthew Stern, Ira Shoulson, Cheryl Deeley, James Pool, Addison Taylor, Catherine Anderson, Alan Forster, Amy Colcher, Jay Beim, Sharron Card, Denyse Turpin, Ted Roberts, Gareth Perry, Dennis J. Esterbrooks & 23 others Syed M. Mohiuddin, Steven Jenkins, Jean Marso, Andrew Siderowf, Mary Matthews, Aryan N. Mooss, Lois Rasmussen, Gretchen Tietjen, Andrea Korsnack, Roger Kurlan, Charlyne Hickey, Marie Saint-Hilaire, Carol Derksen, Brain Maddux, John Brown, Addison Taylor, Catherine Anderson, David Grimes, Marian Evatt, Carol Ingram, Anwar Ahmed, Ruth Kolb, Sheila Belber

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Rasagiline is a novel, potent, and selective MAO-B inhibitor shown to be effective for Parkinson's disease. Traditional nonselective MAO inhibitors have been associated with dietary tyramine interactions that can induce hypertensive reactions. To test safety, tyramine challenges (50-75 mg) were performed in 72 rasagiline-treated and 38 placebo-treated Parkinson's disease (PD) patients at the end of two double-blind placebo-controlled trials of rasagiline. An abnormal pressor response was prespecified as three consecutive measurements of systolic blood pressure (BP) increases of ≥ 30 mm Hg and/or bradycardia of <40 beats/min. In the first study involving 55 patients with early PD on rasagiline monotherapy, no patients randomized to rasagiline (1 mg/ 2 mg; n = 38) or placebo (n = 17) developed systolic BP (SBP) or heart rate changes indicative of a tyramine reaction. In the second trial involving 55 levodopa-treated patients, 3 of 22 subjects on rasagiline 0.5 mg/day and 1 of 21 subjects on placebo developed asymptomatic, self-limiting SBP elevations ≥30 mm Hg on three measurements. No subject on 1 mg/day rasagiline (0/12) experienced significant BP or heart rate changes following tyramine ingestion. These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodova in PD patients without specific dietary tyramine restriction.

Original languageEnglish
Pages (from-to)1716-1721
Number of pages6
JournalMovement Disorders
Volume21
Issue number10
DOIs
StatePublished - Oct 2006

Fingerprint

Tyramine
Monoamine Oxidase Inhibitors
Monoamine Oxidase
Parkinson Disease
Blood Pressure
Placebos
Heart Rate
rasagiline
Levodopa
Bradycardia
Eating
Safety

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Neuroscience(all)

Cite this

deMarcaida, J. A., Schwid, S. R., White, W. B., Blindauer, K., Fahn, S., Kieburtz, K., ... Belber, S. (2006). Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Movement Disorders, 21(10), 1716-1721. https://doi.org/10.1002/mds.21048

Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. / deMarcaida, J. Antonelle; Schwid, Steven R.; White, William B.; Blindauer, Karen; Fahn, Stanley; Kieburtz, Karl; Stern, Matthew; Shoulson, Ira; Deeley, Cheryl; Pool, James; Taylor, Addison; Anderson, Catherine; Forster, Alan; Colcher, Amy; Beim, Jay; Card, Sharron; Turpin, Denyse; Roberts, Ted; Perry, Gareth; Esterbrooks, Dennis J.; Mohiuddin, Syed M.; Jenkins, Steven; Marso, Jean; Siderowf, Andrew; Matthews, Mary; Mooss, Aryan N.; Rasmussen, Lois; Tietjen, Gretchen; Korsnack, Andrea; Kurlan, Roger; Hickey, Charlyne; Saint-Hilaire, Marie; Derksen, Carol; Maddux, Brain; Brown, John; Taylor, Addison; Anderson, Catherine; Grimes, David; Evatt, Marian; Ingram, Carol; Ahmed, Anwar; Kolb, Ruth; Belber, Sheila.

In: Movement Disorders, Vol. 21, No. 10, 10.2006, p. 1716-1721.

Research output: Contribution to journalArticle

deMarcaida, JA, Schwid, SR, White, WB, Blindauer, K, Fahn, S, Kieburtz, K, Stern, M, Shoulson, I, Deeley, C, Pool, J, Taylor, A, Anderson, C, Forster, A, Colcher, A, Beim, J, Card, S, Turpin, D, Roberts, T, Perry, G, Esterbrooks, DJ, Mohiuddin, SM, Jenkins, S, Marso, J, Siderowf, A, Matthews, M, Mooss, AN, Rasmussen, L, Tietjen, G, Korsnack, A, Kurlan, R, Hickey, C, Saint-Hilaire, M, Derksen, C, Maddux, B, Brown, J, Taylor, A, Anderson, C, Grimes, D, Evatt, M, Ingram, C, Ahmed, A, Kolb, R & Belber, S 2006, 'Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline', Movement Disorders, vol. 21, no. 10, pp. 1716-1721. https://doi.org/10.1002/mds.21048
deMarcaida, J. Antonelle ; Schwid, Steven R. ; White, William B. ; Blindauer, Karen ; Fahn, Stanley ; Kieburtz, Karl ; Stern, Matthew ; Shoulson, Ira ; Deeley, Cheryl ; Pool, James ; Taylor, Addison ; Anderson, Catherine ; Forster, Alan ; Colcher, Amy ; Beim, Jay ; Card, Sharron ; Turpin, Denyse ; Roberts, Ted ; Perry, Gareth ; Esterbrooks, Dennis J. ; Mohiuddin, Syed M. ; Jenkins, Steven ; Marso, Jean ; Siderowf, Andrew ; Matthews, Mary ; Mooss, Aryan N. ; Rasmussen, Lois ; Tietjen, Gretchen ; Korsnack, Andrea ; Kurlan, Roger ; Hickey, Charlyne ; Saint-Hilaire, Marie ; Derksen, Carol ; Maddux, Brain ; Brown, John ; Taylor, Addison ; Anderson, Catherine ; Grimes, David ; Evatt, Marian ; Ingram, Carol ; Ahmed, Anwar ; Kolb, Ruth ; Belber, Sheila. / Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. In: Movement Disorders. 2006 ; Vol. 21, No. 10. pp. 1716-1721.
@article{34c41489047e46a2abd40294fe34ae0c,
title = "Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline",
abstract = "Rasagiline is a novel, potent, and selective MAO-B inhibitor shown to be effective for Parkinson's disease. Traditional nonselective MAO inhibitors have been associated with dietary tyramine interactions that can induce hypertensive reactions. To test safety, tyramine challenges (50-75 mg) were performed in 72 rasagiline-treated and 38 placebo-treated Parkinson's disease (PD) patients at the end of two double-blind placebo-controlled trials of rasagiline. An abnormal pressor response was prespecified as three consecutive measurements of systolic blood pressure (BP) increases of ≥ 30 mm Hg and/or bradycardia of <40 beats/min. In the first study involving 55 patients with early PD on rasagiline monotherapy, no patients randomized to rasagiline (1 mg/ 2 mg; n = 38) or placebo (n = 17) developed systolic BP (SBP) or heart rate changes indicative of a tyramine reaction. In the second trial involving 55 levodopa-treated patients, 3 of 22 subjects on rasagiline 0.5 mg/day and 1 of 21 subjects on placebo developed asymptomatic, self-limiting SBP elevations ≥30 mm Hg on three measurements. No subject on 1 mg/day rasagiline (0/12) experienced significant BP or heart rate changes following tyramine ingestion. These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodova in PD patients without specific dietary tyramine restriction.",
author = "deMarcaida, {J. Antonelle} and Schwid, {Steven R.} and White, {William B.} and Karen Blindauer and Stanley Fahn and Karl Kieburtz and Matthew Stern and Ira Shoulson and Cheryl Deeley and James Pool and Addison Taylor and Catherine Anderson and Alan Forster and Amy Colcher and Jay Beim and Sharron Card and Denyse Turpin and Ted Roberts and Gareth Perry and Esterbrooks, {Dennis J.} and Mohiuddin, {Syed M.} and Steven Jenkins and Jean Marso and Andrew Siderowf and Mary Matthews and Mooss, {Aryan N.} and Lois Rasmussen and Gretchen Tietjen and Andrea Korsnack and Roger Kurlan and Charlyne Hickey and Marie Saint-Hilaire and Carol Derksen and Brain Maddux and John Brown and Addison Taylor and Catherine Anderson and David Grimes and Marian Evatt and Carol Ingram and Anwar Ahmed and Ruth Kolb and Sheila Belber",
year = "2006",
month = "10",
doi = "10.1002/mds.21048",
language = "English",
volume = "21",
pages = "1716--1721",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline

AU - deMarcaida, J. Antonelle

AU - Schwid, Steven R.

AU - White, William B.

AU - Blindauer, Karen

AU - Fahn, Stanley

AU - Kieburtz, Karl

AU - Stern, Matthew

AU - Shoulson, Ira

AU - Deeley, Cheryl

AU - Pool, James

AU - Taylor, Addison

AU - Anderson, Catherine

AU - Forster, Alan

AU - Colcher, Amy

AU - Beim, Jay

AU - Card, Sharron

AU - Turpin, Denyse

AU - Roberts, Ted

AU - Perry, Gareth

AU - Esterbrooks, Dennis J.

AU - Mohiuddin, Syed M.

AU - Jenkins, Steven

AU - Marso, Jean

AU - Siderowf, Andrew

AU - Matthews, Mary

AU - Mooss, Aryan N.

AU - Rasmussen, Lois

AU - Tietjen, Gretchen

AU - Korsnack, Andrea

AU - Kurlan, Roger

AU - Hickey, Charlyne

AU - Saint-Hilaire, Marie

AU - Derksen, Carol

AU - Maddux, Brain

AU - Brown, John

AU - Taylor, Addison

AU - Anderson, Catherine

AU - Grimes, David

AU - Evatt, Marian

AU - Ingram, Carol

AU - Ahmed, Anwar

AU - Kolb, Ruth

AU - Belber, Sheila

PY - 2006/10

Y1 - 2006/10

N2 - Rasagiline is a novel, potent, and selective MAO-B inhibitor shown to be effective for Parkinson's disease. Traditional nonselective MAO inhibitors have been associated with dietary tyramine interactions that can induce hypertensive reactions. To test safety, tyramine challenges (50-75 mg) were performed in 72 rasagiline-treated and 38 placebo-treated Parkinson's disease (PD) patients at the end of two double-blind placebo-controlled trials of rasagiline. An abnormal pressor response was prespecified as three consecutive measurements of systolic blood pressure (BP) increases of ≥ 30 mm Hg and/or bradycardia of <40 beats/min. In the first study involving 55 patients with early PD on rasagiline monotherapy, no patients randomized to rasagiline (1 mg/ 2 mg; n = 38) or placebo (n = 17) developed systolic BP (SBP) or heart rate changes indicative of a tyramine reaction. In the second trial involving 55 levodopa-treated patients, 3 of 22 subjects on rasagiline 0.5 mg/day and 1 of 21 subjects on placebo developed asymptomatic, self-limiting SBP elevations ≥30 mm Hg on three measurements. No subject on 1 mg/day rasagiline (0/12) experienced significant BP or heart rate changes following tyramine ingestion. These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodova in PD patients without specific dietary tyramine restriction.

AB - Rasagiline is a novel, potent, and selective MAO-B inhibitor shown to be effective for Parkinson's disease. Traditional nonselective MAO inhibitors have been associated with dietary tyramine interactions that can induce hypertensive reactions. To test safety, tyramine challenges (50-75 mg) were performed in 72 rasagiline-treated and 38 placebo-treated Parkinson's disease (PD) patients at the end of two double-blind placebo-controlled trials of rasagiline. An abnormal pressor response was prespecified as three consecutive measurements of systolic blood pressure (BP) increases of ≥ 30 mm Hg and/or bradycardia of <40 beats/min. In the first study involving 55 patients with early PD on rasagiline monotherapy, no patients randomized to rasagiline (1 mg/ 2 mg; n = 38) or placebo (n = 17) developed systolic BP (SBP) or heart rate changes indicative of a tyramine reaction. In the second trial involving 55 levodopa-treated patients, 3 of 22 subjects on rasagiline 0.5 mg/day and 1 of 21 subjects on placebo developed asymptomatic, self-limiting SBP elevations ≥30 mm Hg on three measurements. No subject on 1 mg/day rasagiline (0/12) experienced significant BP or heart rate changes following tyramine ingestion. These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodova in PD patients without specific dietary tyramine restriction.

UR - http://www.scopus.com/inward/record.url?scp=33750296512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750296512&partnerID=8YFLogxK

U2 - 10.1002/mds.21048

DO - 10.1002/mds.21048

M3 - Article

VL - 21

SP - 1716

EP - 1721

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 10

ER -